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Alpha dystroglycan
Glycosylation
GlycosyltransferaseCongenital muscular dystrophies due to defects in genes encoding proteins involved in α-dystroglycan (α-DG)
glycosylation are a heterogeneous group of muscle disorders variably associated with central nervous system
and eye abnormalities. One of the more severe is muscle-eye-brain disease (MEB). Mutations in genes coding
for proven or putative glycosyltransferases (POMT1, POMT2, POMGnT1, fukutin, FKRP, and LARGE), the DPM3
gene encoding a DOL-P-Man synthase subunit, and the DAG1 gene encoding α-dystroglycan, have been associ-
ated with altered α-DG glycosylation.
We report new POMGnT1mutations and evaluate protein expression in 3 patients and 2 foetuses with variably
severe MEB features. We identify two new point mutations (c.643 C>T, c.1863delC), one new intragenic rear-
rangement (deletion of exons 2–8), and a new intron retention (between exons 21 and 22) resulting from a
known point mutation c.1895+1 G>T. Our study provides further evidence that rearrangements of the
POMGnT1 gene are relatively common. Importantly, if heterozygous, they can be missed on standard genomic
DNA sequencing. POMGNT1 protein analysis in 3 patients showed that the severity of the phenotype does not
correlatewith protein expression. CerebralMRI is important for identifyingMEB andα-dystroglycanopathy phe-
notypes in children and foetuses, and hence for directing the genetic analysis.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Defects in genes coding for proteins involved in the glycosylation of
α-dystroglycan (α-DG) are responsible for a heterogeneous group of
diseases known as α-dystroglycanopathies, part of the wider group of
congenital muscular dystrophies (CMD) [1]. Alpha-dystroglycanopathies
are muscle diseases variably associated with central nervous system and
eye abnormalities [1].
Dystroglycan (consisting of α-DG and β-DG) is an essential compo-
nent of the dystrophin-glycoprotein complex that links the extracellular
matrix to the actin-based cellular cytoskeleton; correct O-linked glyco-
sylation with mannose, on the central mucin-like domain, is key to the
maintenance of membrane stability [2]. Numerous studies on patients
with α-dystroglycanopathies have demonstrated that correct glycosyl-
ation is vital for α-DG function [1,3,4].and Neuroimmunology Unit,
to Neurologico “C. Besta”, Via
fax: +39 02 2394 2619.
Y-NC-ND license.Altered α-DG glycosylation has been associated with mutations in
six genes (POMT1, POMT2, POMGnT1, fukutin, FKRP, and LARGE) that en-
codeproven or putative glycosyltransferases. O-mannosyltransferases 1
and 2 (POMT1, POMT2) are required for the attachment of tetrasaccha-
rides to α-DG. O-mannose beta-1,2-N-acetylglucosaminyltransferase
(POMGnT1) catalyzes the transfer of N-acetylglucosamine (GlcNAc) to
mannose O-linked to α-DG. Fukutin, fukutin-related protein (FKRP)
and LARGE are also thought to be involved in glycosylation, but their
exact function is unknown [3]. Recently, a defect in the DPM3 gene,
coding for a DOL-P-Man synthase subunit, was associated with CMD
in a patient with muscular dystrophy without mental retardation and
greatly reduced α-DG staining on muscle biopsy [5]. Recently also, re-
cessive mutations in DAG1 have been identiﬁed in a patient with re-
duced α-DG on muscle biopsy and a form of limb girdle muscular
dystrophy (LGMD) characterized by severemental retardation, but nor-
mal brain imaging and relatively mild muscular compromise [6].
Conditions associated with altered dystroglycan glycosylation
range from mild LGMD without cognitive impairment, to muscle-
eye-brain disease (MEB) andWalker–Warburg syndrome with severe
brain and eye abnormalities [1,3,7–9]. However, no clear genotype–
phenotype correlations have been found in α-dystroglycanopathies
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tations in individual genes, for example MEB with POMGnT1 [3,8], and
microcephaly plus mental retardation with POMT1 and POMT2 [10].
We now report several new POMGnT1mutations in 3 patients and
2 foetuses with variable but severe MEB features, and evaluate pro-
tein expression in the 3 patients.
2. Patients and methods
Written, informed consent was obtained from subjects or their
parents/legal guardians. The research was conducted according to
protocols approved by the Institutional Review Board of the Besta
Neurological Institute in compliance with the Helsinki Declaration
and Italian legislation.
2.1. Clinical ﬁndings
Cases 1–3. Clinical features are summarized in Table 1. All were
born from healthy, non-consanguineous Italian parents, after un-
eventful pregnancy (case 1), or after detection of brain malformation
and hydrocephaly (case 2), or holoprosencephaly (case 3) on ultra-
sound. In cases 2 and 3 a ventricular-peritoneal shunt was inserted
at 40 and at 20 days, respectively, for hydrocephaly.
All 3 cases had severe psychomotor delay; generalized epileptic
seizures eventually controlledwith antiepileptic drugs also developed
in all. CK levels were moderately elevated. Cerebral magnetic reso-
nance imaging (MRI) showed cerebellar cysts or cerebellar hypoplasia
and widespread abnormalities in the cerebral cortex, in all 3 cases
(Fig. 1). Muscle biopsy revealed increased mainly perimysial connec-
tive tissue, ﬁbre diameter variability, and a few degenerating ﬁbres,
in all cases.
Cases 4 and 5were a female (foetus 1) and amale foetus (foetus 2),
from healthy non-consanguineous Italian parents originating from the
same small village. The ﬁrst pregnancy was terminated at gestational
week 21 because foetal MRI at 20 weeks showed supratentorial hy-
drocephalus, thin cerebral cortex, undetectable corpus callosum, and
hypoplastic and dysmorphic brainstem with posterior kink; the cere-
bellumwas also slightly hypoplastic (Fig. 1). Subsequent autopsy con-
ﬁrmed these alterations and showed other severe brain abnormalities:
type II lissencephaly with neuroglial ectopias in the posterior cerebral
cortex and Sylvian aqueduct, cerebellar hypoplasia, dilatation of the
vermis and agenesis of the culmen. Visceral malformations were not
found.
The presence of an ectopic layer that was thinner than the cortical
layer suggested, together with the MRI ﬁndings, MEB disease or
Walker–Warburg syndrome and a POMGnT1 mutation.
The second pregnancy was terminated at week 20 for ultrasound
abnormalities (corpus callosum agenesis and lateral and third ventric-
ular dilatation) similar to those observed in foetus 1. Autopsy of foetus
2 revealed type II lissencephaly with secondary hydrocephaly, fronto-
temporal neuroglial ectopia, fusion of the cortical frontal lobes, and
thinner ectopic layer than cortical layer, again suggesting a POMGnT1
mutation. The brainstem was thin, with circumferential ectopia andTable 1
Clinical features of the three patients.
Patient/sex Age last seen Clinical features Maximum motor
achievement
Facial d
1/M 30 months Microcephaly, spastic
tetraparesis
Head control Rounde
short n
2/M 17 years, sudden
death at 17
Failure to thrive,
global hypotonia
Postural control
not achieved
None
3/F 9 years Macrocephaly,
tetraparesis
Postural control
not achieved
Frontal
splayed
microgn
* Normal b195 UI.disorganized ﬁbres; the aqueduct was slightly dilated; the arachnoid
was invaginated into the cerebellar folia, the vermis was hypoplastic,
and the cerebellar cortex was dysplastic.
2.2. Immunohistochemistry
Six μm-thick cryosections of muscle were incubated with 2 mono-
clonal anti-laminin-α2 antibodies (Alexis, Lausen, Switzerland; Che-
micon, Temecula, CA, USA) both diluted 1:150, or with 2 anti-α-DG
monoclonal antibodies (clone VIA4-1 and clone IIH6C4 from Upstate
Biotechnology, Charlottesville, VA, USA), both diluted 1:5, then with
biotinylated goat anti-mouse IgG or IgM, as appropriate, diluted
1:250 (Jackson ImmunoResearch Laboratories, West Grove, PA, USA)
and ﬁnally with Rhodamine-Avidin D 1:250 (Vector Laboratories,
Burlingame, CA, USA). Sections were examined under a Zeiss Axioplan
ﬂuorescence microscope.
2.3. Immunoblot
Muscle cryosections were solubilized in lysis buffer, boiled, and
proteins were separated by SDS-PAGE (7.5% for α-DG and 4–15% for
POMGnT1) and transferred to nitrocellulose membranes [11]. The
membranes were probed with primary anti-α-DG antibody (Upstate
Biotechnology, clone IIH6C4, 1:2000) or anti-POMGnT1 (monoclonal
from Santa Cruz, Santa Cruz, CA, USA; 1:100) together with anti-
desmin (monoclonal from Dako Cytomation, Carpinteria, CA, USA;
1:400) or anti-dysferlin (Novocastra Laboratories, Newcastle upon
Tyne, UK; 1:100) as indicators of muscle proteins. Membranes were
then incubated in biotinylated goat anti-mouse IgG or IgM secondary
antibodies (Jackson Labs), followed by streptavidin-HRP (Jackson
Labs), and ECL detection (Amersham, Arlington Heights, IL, USA).
2.4. Molecular analyses
Genomic DNAwas extracted by standardmethods from peripheral
blood lymphocytes, amniocytes or foetal skin. For mutation screening,
primers were designed ﬂanking the intron-exon junctions of each
POMGnT1 exon and the 3′ UTR, based on published sequences (Gen-
Bank accession number: POMGnT1 NM_017739, GenBank reference
POMGNT1 NG_009205.1.gb). PCRs were performed with Mega Mix
Double (Microzone, Haywards Heath, West Sussex, UK). The products
were puriﬁed using microCLEAN (Microzone, Haywards Heath, West
Sussex, UK) and sequenced directly with the BigDye Terminator v1.1
Cycle Sequencing Kit (Applied Biosystems, CA, USA). Sequences were
analyzed on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems,
CA, USA) with Seqscape V2.5 software (Applied Biosystems).
2.5. Quantitative PCR (qPCR)
The intragenic deletion in patient 2 was analyzed by qPCR using
primers for exons 1–9 and ﬂanking regions. Ampliﬁcation products
were analysed with the 7000 Sequence Detection System, ABI Prism
(Applied Biosystems) with SYBR Green (Applied Biosystems). Asysmorphisms Mental retardation Eye involvement CK*
(UI)
d forehead, thin lips,
eck, micrognathia
Severe Retinopathy 1576
Severe Myopia, cataracts,
retinitis pigmentosa
1215
bossing, saddle nose,
nostrils, low-set ears,
athia
Severe, poor response to
sounds and visual stimuli
No eye involvement 702
Fig. 1. MRI of patient 1 (A–D) patient 2 (E, F) and foetus 1 (G, H). (A) Midline sagittal T1-weighted image showing callosal hypogenesis and hypoplastic pons; (B) axial T1-IR
weighted image revealing multiple cerebellar cysts; (C, D) axial T2-weighted images showing irregularity of cortex-white matter junction in frontal lobes, indicative of polymicro-
gyria, and irregular projections of cortex into the underlying white matter in the temporo-parietal-occipital regions indicative of cobblestone lissencephaly. Widespread white mat-
ter hyperintensity is also present. (E) Midline sagittal T1-weighted image showing partial callosal agenesis, hypoplastic brainstem and pons and fused colliculi (note small posterior
fossa and tonsillar ectopia); and (F) axial T2-weighted image demonstrating malformed temporo-occipital-parietal lobes, indicative of polymicrogyria, associated with abnormally
enlarged ventricular spaces. (G) Axial T2-weighted image showing marked ventricular enlargement and cerebral cortex thinning; and (H) sagittal T2-weighted image showing
hypoplastic and dysmorphic brainstem with posterior kinking (20 weeks).
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described by Yanagisawa et al. [12]. gDNA from a healthy individual
was sequenced as control. Results were expressed as normalized
ratio of control to patient. Threshold values were set at 0.8–1.3 for
normal, 0.45–0.74 for deletions and 1.6–1.8 for duplications. Experi-
ments were replicated at least twice if a deletion/duplication was
suspected.
2.6. Multiplex ligation-dependent probe ampliﬁcation (MLPA)
MLPA was performed to screen for large POMGnT1 deletions
according to the manufacturer's instructions using the SALSA MLPA
kit P061 Lissencephaly covering exons 2, 6, 17 and 20 (MRC-Holland,
Amsterdam, The Netherlands).
2.7. cDNA
Total RNA was extracted from skeletal muscle using TRI Reagent
(MRC, Cincinnati, OH). First-strand cDNA synthesis reaction from
total RNA was catalyzed by Transcriptor First Strand cDNA Synthesis
Kit (Roche, Germany). cDNA was ampliﬁed with speciﬁc primers
using Mega Mix Double (Microzone, Haywards Heath, West Sussex,
UK). The PCR products were puriﬁed and sequenced directly with
BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems).
Sequences were analyzed on an ABI Prism 3100 Genetic Analyzer
(Applied Biosystems). When two PCR products were detected, the
agarose gel bands were puriﬁed using QIAquick Gel Extraction Kit
(QIAGEN GmbH, Hilden, Germany) and sequenced.
3. Results
Genomic DNA sequencing excluded mutations in POMT1 and
POMT2 genes of case 1, and in FKRP, POMT1 and POMT2 genes of
cases 2 and 3 (data not shown).Sequence analysis of the POMGnT1 gene in case 1, showed two het-
erozygous null mutations: one maternally-inherited novel c.643 C>T
(p.Arg215X) mutation in exon 7, and a previously reported (Italian;
[8]) paternally-inherited c.931 C>T (p.Arg311X) mutation in exon
10 (Suppl. Fig. 1A). Arg215Xwas also present heterozygously in a ma-
ternal aunt of case 1. The Rescue–ESE software (http://genes.mit.edu/
burgelab/rescue-ese/) for identifying candidate exonic splicing en-
hancers (ESEs), predicted that Arg215X would affect a native ESE and
Arg311Xwould introduce a new ESE. cDNA ampliﬁcation of a fragment
encompassing exons 3–8 of POMGnT1 produced 2 bands, one of the
predicted size and one of smaller size; direct cDNA sequencing of the
2 bands revealed in-frame skipping of exon 7 (Suppl. Fig. 1B). cDNAam-
pliﬁcation of a fragment encompassing exons 7–12 showed that the
Arg311Xmutation did not affect mRNA. Immunohistochemical analysis
showed absence of α-DG and normal expression of the laminin α2
chain (Fig. 2). POMGnT1 antibody did not work in our hands by immu-
nohistochemistry. By immunoblot, the band corresponding to α-DG
had altered mobility and reduced intensity, with 2 extra bands of
lower molecular weight (Fig. 3A); immunoblot of POMGnT1 showed a
band of normal molecular weight and intensity (Fig. 3B).
Sequence analysis of the POMGnT1 gene in case 2 showed an appar-
ently homozygous single bp deletion (c.350delC) in exon 4, previously
reported by us in another Italian case [9], affecting the evolutionarily
conserved Thr117 residue and causing a premature stop codon 26 resi-
dues downstream (Thr117fsX26) (Suppl. Fig. 2A). POMGnT1 sequenc-
ing in the father showed the mutation to be heterozygous; however,
sequencing of the mother DNA failed to reveal this alteration. The mu-
tation was also present heterozygously in a healthy sister of the case.
We therefore supposed that intragenic rearrangement had caused the
proband to be compound heterozygous and that a second mutation
was present. cDNA ampliﬁcation of fragments encompassing exons
1–9, 1–5, 3–8, 1–12 failed to reveal any band of smaller size. Direct
cDNA sequencing showed the presence of the point mutation, but no
rearrangements. However qPCR analysis revealed that exons 2–8
Fig. 2. Muscle immunohistochemistry in control and patients 1, 2 and 3 with VIA4-1 (left column), IIH6C4 (central column), anti-α-DG and anti-laminin α2 chain (right column)
antibodies, showing absence of α-DG in all patients, and normal laminin α2 in patients 1 and 3, and slightly reduced laminin α2 expression in patient 2. X200.
Fig. 3. α-DG (A) and POMGnT1 (B) immunoblots of muscle from control and the 3 pa-
tients showing variably altered mobility and reduced intensity of α-DG in all cases, and
a POMGnT1 band of normal molecular weight and intensity in patient 1; 2 bands of re-
duced intensity, one of normal and one of reduced molecular weight (asterisk) in pa-
tient 2; and an almost undetectable band of normal molecular weight in patient 3.
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MLPA analysis conﬁrmed a heterozygous deletion of exons 2 and 6,
while exons 17 and 20 were normal (the commercial MLPA kit only
contains probes for exons 2, 6, 17 and 20) (Suppl. Fig. 2C). Case 2 is
therefore compound heterozygous for a point mutation in exon 4 and
a large deletion of exons 2–8. By immunohistochemistry α-DG was ab-
sent and the laminin α2 chain was slightly reduced (Fig. 2). By immu-
noblot, the band corresponding to α-DG had altered mobility and
reduced intensity (Fig. 3 A); immunoblot of POMGnT1 showed two
bands of reduced intensity, one of normal (almost undetectable) and
one of reduced molecular weight (approx. 47 kD) (Fig. 3B).
Sequence analysis of POMGnT1 in case 3 showed the same point
mutation as case 2, paternally inherited, and a previously reported
maternally inherited mutation [13], presumed to affect pre-mRNA
splicing (c.1895+1 G>T) (Suppl. Fig. 3A). PCR of the 16–22 exon
cDNA fragment showed a band of higher molecular weight that,
after extraction and sequencing, showed that the intron between
exons 21 and 22 was retained (Suppl. Fig. 3B). By immunohistochem-
istry α-DG was absent and the laminin α2 chain was normally
expressed (Fig. 2). Immunoblot of α-DG showed a band of altered
mobility and reduced intensity (Fig. 3 A); immunoblot of POMGnT1
showed an almost undetectable band of normal molecular weight
(Fig. 3 B).
Sequence analysis of POMGnT1 in cases 4 and 5 revealed a novel
homozygous stop mutation in exon 21, c.1863delC (Leu622X)
(Suppl. Fig. 3C). Sequencing of the mother and father's DNA con-
ﬁrmed that the mutation was present heterozygously in both. We
could not perform immunochemical analysis for lack of tissue.
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MEB was ﬁrst described in 1989 in Finland by Santavuori [14] and
was later shown to be caused bymutations in the POMGnT1 gene [15].
It is now known that genes involved in α-DG glycosylation can also
cause MEB. MEB patients present as ﬂoppy infants with visual prob-
lems, severe mental retardation, dystrophic changes on muscle biop-
sy, and multiple structural abnormalities of the brain [4,7,13–15].
Numerous patients with POMGnT1mutations have been identiﬁed
worldwide, and the clinical spectrum ranges from severe conditions
similar to Walker–Warburg syndrome or Fukuyama CMD, through
classic MEB, to the relatively mild LGMD phenotype [4,7,13].
Our study on 3 Italian MEB patients and 2 foetuses has identiﬁed
two new point mutations, one new large intragenic deletion, and a
new intron retention resulting from a previously-reported point mu-
tation. Our ﬁndings indicate that intragenic rearrangements of genes
related to α-DG glycosylation may be relatively common [12,16] and
provide further evidence that POMGnT1mutations are usually associ-
ated with severe MEB-like features. Cases 1 and 3 were severely
affected, case 2 survived until age 17, and both foetuses had very
severe central nervous system defects.
Our study also provides further evidence that cerebral MRI is im-
portant for diagnosing CMD and α-dystroglycanopathies [17]. The
combination of brainstem hypoplasia, diffuse polymicrogyria, white
matter alterations, hydrocephalus, and cerebellar cysts, although pre-
sent in patients with mutations in other α-DG-related genes, is more
common in POMGnT1-mutated cases and should direct the genetic in-
vestigations accordingly [4,17]. Foetal pathological ﬁndings and MRI
alterations were also highly suggestive of α-DG-related defects and,
since POMT1 and POMT2mutations in foetal cases are usually associat-
ed with the more severe Walker–Warburg phenotype [18], POMGnT1
was the ﬁrst gene targeted in our genetic analysis.
To our knowledge, our study is the ﬁrst to assess POMGnT1 protein
expression in patient muscle. We found that the severity of the pheno-
type did not correlate with POMGnT1 protein expression. Thus case 1,
with typicalMEB phenotype, had apparently normal protein expression
so the disease is almost certainly attributable to reduced enzyme activ-
ity. In fact, the Arg215Stop mutation, present in case 1, causes skipping
of exon 7 to produce a protein lacking 40 amino acids in the stem do-
main crucial for enzyme activity [19,20]. The band of apparently normal
molecular weight present onWestern blot probably corresponds to this
shortened protein: the short course of the gel was likely insufﬁcient to
resolve it from the normal protein. Furthermore, because the stem do-
main is also involved in enzyme localization, the mutated protein may
not be transported to its normal location in the Golgi apparatus [20].
The previously described [8] secondmutation in case 1, c.931 C>T
in exon 10 produces a p.Arg311Stop in the highly conservedGnT-1 do-
main of POMGnT1 that is thought to be essential for UDP-GlcNAc and
Mn2+ binding. This amino acid is highly conserved in many species
[21] and has been reported mutated in two other patients, suggesting
mutational hot spot [8,21]. Biochemical studies on truncated mutant
variants of the human enzyme have shown that this residue is in-
volved in the regulation of its activity [2,20].
The two mutations in case 1 are therefore compatible with the
patient's severe clinical features and with the altered α-DG glycosyl-
ation shown by immunohistochemistry and Western blot data.
The c.350delCmutation producing Thr117fsX26 in case 2 is a novel
stop mutation predicted to produce a truncated protein lacking the
entire catalytic domain and part of the stem domain. We were unable
to detect a band corresponding to this truncated protein by Western
blot probably because it is unstable. The normal molecular weight
band of greatly reduced intensity observed in this patient may have
been produced by low levels of POMGnT1 transcript that either es-
caped nonsense-mediated decay [22] or underwent alternative trans-
lational initiation [23]. The second mutation in case 2 is an intragenic
deletion encompassing exons 2 to 8. The predicted protein [20] wouldhave reducedmolecular weight (conﬁrmed byWestern blot), be solu-
ble (transmembrane domain missing) and also retain enzymatic
activity and perhaps retain some function.
Case 3 has the same stop mutation (c.350delC) as case 2, as well as
the previously reported c.1895+1 G>T, which we have shown to af-
fect RNA splicing causing retention of intron 22. We found a very faint
POMGnT1 band of normal molecular weight on Western blot. The se-
vere phenotype in this patient is probably related to almost total lack
of POMGnT1 protein and hence massively reducedα-DG glycosylation.
In cases 4 and 5 with closely similar phenotype the new homozy-
gous stop mutation Leu622X introduces a premature stop codon in
exon 21, which is presumed to give rise to a protein lacking part of
the catalytic domain and hence reduced or absent enzyme activity.
Both foetuses had severe brain malformations and were aborted. Un-
fortunately no muscle tissue was available for analysis.
To conclude, our study provides further evidence that rearrange-
ments of the POMGnT1 gene are relatively common. Importantly,
they can bemissed on standard sequencing of genomic DNA if hetero-
zygous, as in our case 2. POMGNT1 protein analysis in 3 patients has
shown that the severity of the phenotype does not correlate with pro-
tein expression. Cerebral MRI is conﬁrmed as important for identify-
ing MEB and α-dystroglycanopathy phenotypes in both children
and foetuses and hence for directing the genetic analysis.
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.jns.2012.04.008.
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